The pharmacological management of oppositional behaviour, conduct problems, and aggression in Children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 1: Psychostimulants, alpha-2 agonists, and atomoxetine

Canadian Journal of Psychiatry

Volumn 60, Issue 2, 2015, Pages 42-51

  Pringsheim, Tamara ^a,b   Hirsch, Lauren ^a   Gardner, David ^c   Gorman, Daniel A ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b Calgary Tourette and Pediatric Movement Disorders Clinic   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alpha 2 agonists; Atomoxetine; Attentiondeficit hyperactivity disorder; Clonidine; Conduct disorder; Guanfacine; Meta analysis; Oppositional defiant disorder; Psychostimulants; Systematic review

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ATOMOXETINE; CLONIDINE; GUANFACINE; PSYCHOSTIMULANT AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT;

ADOLESCENT; AGGRESSION; ATTENTION DEFICIT DISORDER; CHILD; CONDUCT DISORDER; DRUG EFFECT; DRUG USE; HUMAN; META ANALYSIS; OPPOSITIONAL DEFIANT DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG EFFECTS;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; AGGRESSION; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CONDUCT DISORDER; HUMANS;

EID: 84922640478     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371506000202     Document Type: Review

References (31)

1. Brault MC, Lacourse E. Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994-2007. Can J Psychiatry. 2012;57(2):93-101.
2. Maughan B, Rowe R, Messer J, et al. Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology. J Child Psychol Psychiatry. 2004;45(3):609-621.
3. Canadian Attention Deficit Hyperactivity Disorder Research Alliance (CADDRA). Canadian ADHD practice guidelines. 3rd ed. Toronto (ON): CADDRA; 2011.
4. Pringsheim T, Hirsch L, Gardner DM, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attentiondeficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatry. 2015;60(2):52-61.
5. Kung J, Chiappelli F, Cajulis OO, et al. From systematic reviews to clinical recommendations for evidence-based health care: validation of Revised Assessment of Multiple Systematic Reviews (R-AMSTAR) for grading of clinical relevance. Open Dent J. 2010;4:84-91.
6. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-394.
7. Conners CK. Conners. 3rd ed. Toronto (ON): Multi-Health Systems Inc; 2008.
8. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviours in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253-261.
9. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol. 2005;13(2):111-126.
10. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82-90.
11. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883-892.
12. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284-1293.
13. Erratum in: J Am Acad Child Adolesc Psychiatry. 2007;46(1):141.
14. Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006;15(8):450-459.
15. Sinzig J, Dopfner M, Lehmkuhl G. Long-acting methylphenidate has an effect on aggressive behavior in children with attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(4):421-432.
16. Evans SW, Pelham WE, Smith BH, et al. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001;9(2):163-175.
17. Gorman EB, Klorman R, Thatcher JE, et al. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):808-816.
18. Palumbo D, Sallee F, Pelham W, et al. Clonidine for attentiondeficit/hyperactivity disorder: I. Efficacy and tolerability. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180-188.
19. Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(2):209-216.
20. Gadow KD, Sverd J, Nolan EE, et al. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):840-848.
21. Lopez FA, Ginsbeg LD, Arnold VA. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. Postgrad Med. 2008;120(3):89-102.
22. Agarwal V, Sitholey P, Kumar S, et al. Double-blind, placebocontrolled trial of clonidine in hyperactive children with mental retardation. Ment Retard. 2001;39(4):259-267.
23. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886-894.
24. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry. 1985;24(5):617-629.
25. Kollins S, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406-e1413.
26. Kurlan R. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527-536.
27. Wilens T, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74-85.
28. Connor DF, Findling RL, Kollins S, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755-768.
29. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174-187.
30. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care [Internet]. Medscape Psychiatry & Mental Health; 2003 [cited 2014 Jun. 25]. Available from: http://www.medscape.com/psychiatry.
31. Seixas M, Weiss M, Muller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012;26(6):753-765.